JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M203060200 on April 12, 2002

J. Biol. Chem., Vol. 277, Issue 25, 22484-22490, June 21, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/25/22484    most recent
M203060200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sawa, C.
Right arrow Articles by Handa, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sawa, C.
Right arrow Articles by Handa, H.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

YEAF1/RYBP and YAF-2 Are Functionally Distinct Members of a Cofactor Family for the YY1 and E4TF1/hGABP Transcription Factors*

Chika SawaDagger, Tatsufumi Yoshikawa, Fumihiko Matsuda-Suzuki, Sophie Deléhouzée, Masahide Goto, Hajime Watanabe§, Jun-ichi Sawada, Kohsuke Kataoka||, and Hiroshi Handa||**

From the Faculty of Bioscience and Biotechnology and || Frontier Collaborative Research Center, Tokyo Institute of Technology, 4259 Nagatsuta-cho, Midori-ku, Yokohama 226-8501 and § National Institute for Basic Biology, Okazaki National Research Institutes, 38 Myodaiji, Okazaki 444-8585, Japan

Received for publication, March 29, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The transcription factor hGABP/E4TF1 is a heterotetrameric complex composed of two DNA-binding subunits (hGABPalpha /E4TF1-60) and two transactivating subunits (hGABPbeta /E4TF1-53). In order to understand the molecular mechanism of transcriptional regulation by hGABP, we searched for proteins that interact with the non-DNA-binding subunit, hGABPbeta , using yeast two-hybrid screening. We identified a human cDNA encoding a protein related to YAF-2 (YY1-associated factor 2), which was previously isolated as an interacting partner of the Ying-Yang-1 (YY1) transcription factor. Reflecting this similarity, both YAF-2 and this novel protein (named YEAF1 for YY1- and E4TF1/hGABP-associated factor-1) interacted with hGABPbeta and YY1 in vitro and in vivo, indicating that YEAF1 and YAF-2 constitute a cofactor family for these two structurally distinct transcription factors. By using yeast three-hybrid assay, we demonstrated that hGABPbeta and YY1 formed a complex only in the presence of YEAF1, indicating that YEAF1 is a bridging factor of these two transcription factors. These cofactors are functionally different in that YAF-2 positively regulates the transcriptional activity of hGABP but YEAF1 negatively regulates this activity. Also, YAF-2 mRNA is highly expressed in skeletal muscle, whereas YEAF1 mRNA is highly expressed in placenta. We speculate that the transcriptional activity of hGABP is in part regulated by the expression levels of these tissue-specific cofactors. These results provide a novel mechanism of transcriptional regulation by functionally distinct cofactor family members.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

E4TF1 was originally purified from HeLa cells and was identified as one of the sequence-specific transcription factors that bind to and stimulate transcription from the adenovirus early 4 (E4)1 promoter (1, 2). Subsequent cDNA cloning and nucleotide sequence analyses (3, 4) have revealed that it is a human homologue of the rat GA-binding protein (hGABP), which binds to the GA motif of the herpes simplex virus immediate early genes and stimulates their transcription (5, 6).

E4TF1/hGABP is a unique transcription factor in its subunit composition. It is a heterotetramer (alpha 2beta 2) of two 60-kDa (E4TF1-60/hGABPalpha ) and two 53-kDa (E4TF1-53/hGABPbeta ) subunits. Structural and biochemical analyses (3, 4, 7, 8) have revealed that hGABPalpha contains an Ets-related DNA-binding domain and can bind to the DNA sequence 5'-CGGAAGTG-3'. However, hGABPalpha alone is unable to activate transcription, and the transactivator function is conferred by the formation of a heterotetramer with hGABPbeta . In contrast to hGABPalpha , hGABPbeta alone cannot bind to DNA, but it forms a homodimer through its leucine zipper-like structure at the carboxyl terminus and forms a heterodimer with hGABPalpha through its Notch/ankyrin repeat motif at the amino terminus. The resultant alpha 2beta 2 heterotetramer has the capacity to activate transcription. Another non-DNA-binding subunit of 47 kDa, E4TF1-47/GABPgamma , is structurally identical to hGABPbeta except that it differs at its carboxyl extremity and lacks the homodimerization domain. GABPgamma retains the ability to form a heterodimer with hGABPalpha but the resultant alpha gamma heterodimer cannot activate transcription. The subunit composition is therefore one mechanism for the regulation of the transcriptional activity of hGABP (4, 7, 8).

In addition to the adenovirus E4 gene and the herpes simplex virus immediate early genes, an increasing number of cellular genes have been found to be targets of E4TF1/hGABP. In accordance with the fact that E4TF1/hGABP is a ubiquitously expressed transcription factor, its targets include ubiquitously expressed genes such as the genes for cytochrome c oxidase subunits IV and Vb (9), the ATP synthase beta -subunit (10), ribosomal proteins L30 and L32 (11), and the retinoblastoma tumor suppressor protein (12, 13). However, some tissue-specific genes, such as male-specific steroid 16alpha -hydroxylase (14), leukocyte-specific cell adhesion molecule CD18 (beta 2 integrin) (15), neutrophil elastase (16), interleukin-2 (17), utrophin (18, 19), and nicotinic acetylcholine receptor subunits (20), have also been demonstrated to be regulated by E4TF1/hGABP. Despite accumulating evidence for both ubiquitous and tissue-specific gene regulation by E4TF1/hGABP, how this regulation is achieved is still unknown.

One of the most likely control mechanisms of such transcriptional regulation is an interaction with other transcription factors. In fact, we and others have demonstrated that E4TF1/hGABP synergistically activates transcription through physical interaction with the ATF1, CREB (21), SP1 (22), SP3 (23), and HCF transcription factors (24). In contrast, E4TF1/hGABP activity is inhibited by interaction with the mi transcription factor (MITF) in mast cells (25).

To understand the mechanism of transcriptional regulation by E4TF1/hGABP, it is important to clarify the regulatory cross-talk that occurs with other transcription factors and cofactors. To this end, we screened a cDNA expression library for genes whose products interact with the hGABPbeta subunit, and we isolated a cofactor, YEAF1/RYBP. We demonstrate here that YEAF1/RYBP represses the transcriptional activity of E4TF1/hGABP, whereas its close relative, YAF-2 (26), activates the activity of E4TF1/hGABP. These results provide the first example of a cofactor family with functionally distinct members.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Yeast Two-hybrid Screening and Interaction Assay-- A yeast two-hybrid screen was performed using a modified version of the system of Fields and Song (27). Briefly, pBTM116/hGABPbeta -(249-383), encoding a LexA-fusion protein with amino acids 249-383 of hGABPbeta , was transformed into the yeast strain L40 by the lithium acetate method. The resultant strain was then transformed with a GAL4-activation domain fusion cDNA library constructed from mRNAs of HeLa cells (MATCHMAKER HL4000AA, CLONTECH). The transformants were plated onto a selective medium for histidine prototrophy (-Trp, -Leu, -Ura, -Lys, -His, and 10 mM 3-aminotriazole (3-AT)) and were incubated at 30 °C for 5 days. His+ colonies were then grown in a liquid selective (-Trp, -Leu) medium until the A600 reached 1.0 to 1.2 and were further tested for beta -galactosidase activity as described previously (13). Each GAL4 fusion prey plasmid was rescued from the 3-AT-resistant and beta -galactosidase-positive yeast clones and transformed into Escherichia coli (DH5alpha ).

For the interaction assay, the L40 yeast strain was transformed with an appropriate LexA fusion plasmid and GAL4-activation domain fusion plasmid (pGAD424; CLONTECH) and was plated onto a selective medium (-Trp, -Leu). Three independent transformed colonies were then assayed for 3-AT sensitivity and beta -galactosidase activity.

For three-hybrid assay, pBridge Three-Hybrid Vector (CLONTECH) was used to express GAL4-DNA-binding domain fusion and bridge proteins. The expression of the bridge protein can be inhibited by addition of methionine into the medium.

Plasmids-- LexA fusion or GAL4-activation domain fusion plasmids used for yeast two-hybrid interaction assays were constructed by insertion of PCR-amplified fragments into appropriate sites of pBTM116 (a generous gift of Dr. Hollenberg) or pGAD424 (CLONTECH), respectively. A human YY1 cDNA (28) was a gift from Dr. T. Shenk. A human YAF-2 cDNA was obtained by screening a HeLa cDNA library using a YEAF1 cDNA probe.

Surface Plasmon Resonance Analysis-- An EcoRI-XhoI fragment containing a full-length YEAF1 open reading frame was excised from pGAD424/YEAF1 and inserted into EcoRI/XhoI-digested pGEX5X3 to make pGEX5X3/YEAF1. A glutathione S-transferase (GST)-YEAF1 protein was expressed in E. coli BL21 (DE3) and purified. GST-YEAF1 was then immobilized onto Sensor Chip CM5 (Biacore AB) (~2500 resonance units) via an anti-GST antibody, and the chip was used to analyze the interaction using BIACORE2000 as described previously (8). Recombinant hGABPbeta and hGABPgamma proteins expressed in E. coli were prepared as described previously (3).

Immunoprecipitation and Western Blotting-- A mammalian expression plasmid for FLAG-tagged YEAF1 was constructed by inserting a FLAG sequence and YEAF1 cDNA fragment into a pCAGGS vector. Four micrograms of the resultant plasmid pCAGGS/FLAG-YEAF1 or of pCAGGS/FLAG, which expresses the FLAG peptide only, was transfected into 1 × 105 HeLa cells in a 100-mm dish using the Effectene reagent (Qiagen). Forty eight hours after transfection, cells were lysed with 500 µl of lysis buffer (20 mM HEPES, pH 7.9, 50 mM KCl, 10 µM ZnSO4, 1 mM phenylmethylsulfonyl fluoride, 1 µg/ml pepstatin, 1.0% Nonidet P-40). The total cell extract (400 µl) was incubated with 20 µl of anti-FLAG M2 antibody-conjugated resin (Sigma) for 8 h at 4 °C, and the resin was washed three times with wash buffer (20 mM HEPES, pH 7.9, 50 mM KCl, 10 µM ZnSO4, 1 mM phenylmethylsulfonyl fluoride, 1 µg/ml pepstatin, 0.01% Nonidet P-40). The precipitated complex was eluted by boiling the resin in 40 µl of SDS sample buffer. The eluate and the total cell extract were separated on a 10% SDS-polyacrylamide gel, transferred to a polyvinylidene difluoride membrane, and stained with monoclonal mouse anti-FLAG (Sigma), monoclonal mouse anti-hGABPbeta , or polyclonal rabbit anti-YY1 (Santa Cruz Biotechnology) antibodies using ECL detection reagents (Amersham Biosciences).

Luciferase Assay-- Transfection of Schneider's 2 (SL2) Drosophila melanogaster cells, the luciferase assay, and the beta -galactosidase assay were performed as described previously (7). A luciferase reporter plasmid containing the human retinoblastoma susceptibility (Rb) gene promoter (pRB-luciferase) and expression plasmids for hGABPbeta , hGABPgamma , and hGABPalpha have also been described (12). The expression plasmids in fly cells for YEAF1, YEAF1 (CR1OR), and YAF-2 (A5CDelta P/YEAF1, A5CDelta P/YEAF1 (CR1OR), and A5CDelta P/YAF-2) were constructed by inserting each DNA fragment into an A5CDelta P expression plasmid.

Northern Blot Analysis-- A human multiple tissue Northern blot (CLONTECH) was hybridized with 32P-labeled YEAF1, YAF-2, hGABPbeta , and actin cDNA probes as recommended by the manufacturer.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Isolation of YEAF1, a Novel Factor Interacting with the hGABPbeta Subunit-- In order to understand the mechanism of transcriptional regulation by E4TF1/hGABP, it is important to clarify the regulatory cross-talk that occurs with other transcription factors and/or cofactors. We used the yeast two-hybrid method to screen a cDNA expression library for genes whose products interact with the non-DNA-binding subunit of E4TF1/hGABP (E4TF1-53/hGABP). We used an amino-terminally truncated form of hGABPbeta as bait (LexA-hGABPbeta -(249-383)) to avoid interaction with the DNA-binding subunit hGABPalpha . This fusion product retains the transactivator and self-association domains (see Fig. 2A). By screening a HeLa cDNA library, we obtained 33 positive colonies out of ~1 × 106 transformants. Isolation of the plasmids and subsequent restriction-digestion analysis of the inserted cDNAs revealed that all of these plasmids contained a single cDNA species of 1.1 kb in length. Nucleotide sequencing analysis revealed that this was a novel cDNA that showed similarity to the previously identified YY1-associated factor (YAF-2) (26).

By plaque hybridization using this partial cDNA fragment as a probe and 3'-rapid amplification of cDNA ends, we obtained a cDNA contig of 4765 bp (data not shown, GenBankTM accession number AB029551). The cDNA contig (designated as YY1 and E4TF1/hGABP associated factor-1 (YEAF1), see below) contained a putative poly(A) addition signal and poly(A) stretch at the 3' end of the cDNA and two ATG codons at the 5' end of its single open reading frame. We speculated that the second ATG codon might be the initiator codon, because it showed similarity to the putative initiator codon of YAF-2 (26), and its surrounding sequence completely matches the Kozak's consensus sequence. Based on this information and the mRNA length predicted from a Northern blot analysis (5.0 kb, see below), we believe that we obtained nearly full-length cDNA. The YEAF1 protein contained no significant protein motif other than two potential zinc fingers at its amino-terminal region (Fig. 1A).


View larger version (55K):
[in this window]
[in a new window]
 
Fig. 1.   Similarity of YEAF1 and YAF-2. A, the deduced amino acid sequence of YEAF1 and its comparison with YAF-2. The conserved cysteine residues in the zinc finger motif are indicated by asterisks. B, schematic representation of YEAF1 and YAF-2. CR1 and CR2, conserved region 1 and 2; YEAF1 OR, YEAF1 original region.

As mentioned above, the protein was similar to the YAF-2 protein (Fig. 1A) reported previously (26). YEAF1 and YAF-2 shared the highest homology at the amino-terminal domain containing the two zinc finger motifs and moderate similarity at the carboxyl-terminal domain, which we refer to as conserved region (CR) 1 and 2, respectively (Fig. 1B). YEAF1 also contains a unique region between CR1 and CR2 that is absent in YAF-2, and we refer to this as the YEAF1 original region (OR) (Fig. 1B). Later on, YEAF1 was found to be highly homologous to mouse RYBP (Ring1 and YY1-binding protein) (29), indicating that YEAF1 and RYBP are species homologues.

YEAF1 Interacts with Both hGABPbeta and hGABPgamma but Not with hGABPalpha -- Specific binding of YEAF1 to hGABPbeta was verified by the yeast two-hybrid assay as monitored by 3-AT sensitivity and by beta -galactosidase assay (Fig. 2, A and B). A GAL4AD-YEAF1 fusion protein interacted with a LexA fusion protein of full-length hGABPbeta and an amino-terminally truncated hGABPbeta -(249-383) that was used as bait for two-hybrid screening, indicating that the amino-terminal ankyrin repeat motifs required for interaction with hGABPalpha are dispensable for interaction with YEAF1. A more extensive amino-terminal deletion mutant, hGABPbeta -(311-383), no longer associated with YEAF1 despite retaining the leucine zipper-like structure required for homodimerization and transactivation. These results indicate that a region of hGABPbeta spanning amino acids 249-310 is required for association with YEAF1. Accordingly, hGABPgamma , an alternatively spliced form of hGABPbeta that retains this region but lacks the abilities to form homodimer and to transactivate, was able to interact with YEAF1.


View larger version (47K):
[in this window]
[in a new window]
 
Fig. 2.   Interaction of YEAF1 with hGABP and YY1. A, schematic structure of the hGABP subunits and the deletion mutants used for the yeast two-hybrid interaction assay. Previously identified structural motifs such as the ankyrin repeat motif (Ank-repeat), leucine zipper structure (Leu zipper), and nuclear localization signal (NLS) are shown. B, yeast two-hybrid interaction assay. Yeast strains doubly transformed with the indicated LexA fusion and GAL4-activation domain (AD) fusion plasmids were tested for growth on culture plates in the presence or absence of 3-aminotriazole (3-AT) (left panel) or for beta -galactosidase (beta -gal) activity (right panel).

In contrast, the LexA fusion of the DNA-binding subunit hGABPalpha did not interact with GAL4AD-YEAF1, although it did interact with GAL4AD-hGABPbeta (data not shown). Furthermore, we could not detect an interaction of YEAF1 with the unrelated ATF1 transcription factor (Fig. 2B) nor with the alpha - and beta -subunits of casein kinase II (data not shown). These results indicate that YEAF1 specifically interacts with hGABPbeta .

We also found that YEAF1 interacts with YY1 (Fig. 2B), as would be expected based on its similarity to YAF-2, which was originally identified as an interacting partner of YY1 (26). Therefore, YEAF1 interacts with both hGABPbeta and YY1. From these observations, we designated this protein YEAF1 (for YY1- and E4TF1/hGABP-associated factor-1).

hGABPbeta Associates with Both YEAF1 and YAF-2-- We next determined the domain of YEAF1 that is required for association with hGABPbeta . A series of deletion mutants of YEAF1 were fused to GAL4AD and were assayed for interaction with LexA-hGABPbeta in yeast (Fig. 3A). As was evident by both 3-AT sensitivity and by beta -galactosidase assays (Fig. 3B), the carboxyl-terminal conserved region 2 (CR2) of YEAF1 was necessary for interaction with hGABPbeta .


View larger version (49K):
[in this window]
[in a new window]
 
Fig. 3.   Both YEAF1 and YAF-2 interact with hGABPbeta . A, YEAF1 mutants and YAF-2, shown schematically, were fused to a GAL4-activation domain for the interaction assay. B, the 3-AT sensitivity (left panel) and beta -galactosidase activity (right panel) of yeast strains expressing the indicated fusion constructs. WT, wild type.

The fact that the CR2 of YEAF1 has sequence similarity with the corresponding region of YAF-2 prompted us to test the interaction of YAF-2 and hGABPbeta . As expected, we were able to detect the interaction of the GAL4AD-YAF-2 and LexA-hGABPbeta fusion proteins by a yeast two-hybrid assay (Fig. 3B). Therefore, YEAF1 and YAF-2 constitute a protein family that specifically interacts with the hGABP transcription factor.

Kinetic Analysis of Binding of YEAF1 with hGABPbeta and hGABPgamma -- We next analyzed the kinetics of the hGABPbeta and YEAF1 interaction using surface plasmon resonance (SPR). A purified recombinant GST fusion protein with full-length YEAF1 (GST-YEAF1) was immobilized onto the sensor chip surface via a previously coupled anti-GST antibody. By injecting purified recombinant hGABPbeta protein at various concentrations into the immobilized or control sensor chips, we measured real time SPR at the association and dissociation phases of interaction of hGABPbeta and YEAF1. Fig. 4A shows the sensorgrams obtained by subtracting the background values. The specific interaction of hGABPbeta and YEAF1 was dose-dependent, indicating that hGABPbeta and YEAF1 bind directly in vitro. From these sensorgrams, the kd, ka, and KD values of the hGABPbeta /YEAF1 interaction were calculated (Fig. 4B) and are summarized in Fig. 4C, together with values previously obtained using hGABPbeta and hGABPalpha (8). The equilibrium dissociation constant (KD) value of hGABPbeta and YEAF1 was 8.0 × 10-9 M, which is about 10 times higher than the KD value for the hGABPbeta and hGABPalpha subunits.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 4.   Kinetic analysis of hGABP-YEAF1 interaction using the SPR system. A, sensorgrams obtained by a sensor chip immobilized with 2500 resonance units of GST-YEAF-1 protein and various concentrations of recombinant hGABPbeta solution. B, plots of ks against concentration of hGABPbeta calculated from the sensorgram. The slope value in a plot of ln(dR/dt) against t (time) is expressed as -ks, where R is the resonance unit. The slope gives the association rate constant. C, kinetic parameters of the interaction of YEAF1 with hGABPbeta and hGABPgamma determined by SPR analyses. The previously determined values for the interaction of hGABPalpha with hGABPbeta and with its recognition DNA sequence are shown for comparison (8).

We also analyzed the interaction between hGABPgamma and YEAF1 in a similar manner, and we obtained a similar KD value (3.7 × 10-9 M) (Fig. 4C and data not shown).

Interaction of YEAF1 with Both hGABP and YY1 in Vivo-- To test whether YEAF1 forms a functional complex with hGABPbeta or YY1 in vivo, we first constructed an expression plasmid containing FLAG-tagged full-length YEAF1 protein and transfected the plasmid into HeLa cells. Immunofluorescent staining of the transfected cells with an anti-FLAG antibody revealed that the FLAG-YEAF1 protein is predominantly localized in the nucleus (data not shown). Similar nuclear staining was observed when using COS-1 cells transfected with a full-length YEAF1 expression plasmid (without the tag) and anti-YEAF1 antiserum (data not shown). Nuclear localization of YEAF1 seems quite reasonable because both hGABP and YY1 are nuclear transcription factors.

We then prepared nuclear extracts from the transfected cells and subjected them to immunoprecipitation using the anti-FLAG antibody. Aliquots of the precipitate were analyzed by immunoblotting with anti-FLAG, anti-hGABPbeta , and anti-YY1 antisera. As shown in Fig. 5, both hGABPbeta and YY1 were detected in the anti-FLAG precipitate but not in the control precipitate, demonstrating that YEAF1 forms a complex with both hGABPbeta and YY1 in the nucleus.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 5.   Interaction of YEAF1 with hGABPbeta and YY1 in vivo. HeLa cells were transfected with expression vectors for FLAG peptide (-) or FLAG-YEAF1 (+). Total cell extracts (input) or the fractions immunoprecipitated by an anti-FLAG antibody (ppt) were immunoblotted with the antibodies indicated at the left.

Ternary Complex Formation of hGABP, YEAF1, and YY1-- The result shown above does not necessarily indicate that hGABP, YEAF1, and YY1 form a ternary complex. To test this possibility, we performed a yeast three-hybrid assay schematically show in Fig. 6A. In addition to the GAL4DB and GAL4AD fusion proteins, the third protein ("bridge" protein) is expressed in yeast to test a ternary complex formation. The expression of the bridge protein can be down-regulated by addition of methionine into the medium.


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 6.   Ternary complex formation of hGABP, YEAF1, and YY1. A, schematic representation of a yeast three-hybrid assay. Expression level of the Bridge protein can be controlled by addition of methionine (+Met) into the medium. DB-fusion, GAL4-DNA-binding domain (DB) fusion; AD- fusion, GAL4-activation domain (AD) fusion. B, beta -galactosidase (beta -gal) activity of yeast strains expressing the indicated fusion and bridge proteins.

The background beta -galactosidase activity was relatively high because full-length hGABPbeta was fused to the GAL4DB, and we could see no evidence for interaction of the GAL4DB-hGABPbeta with the GAL4AD-YY1 (Fig. 6B, lane 1). Co-expression of an intact YEAF1 protein resulted in significant beta -galactosidase expression, and reduction of the YEAF1 expression level by addition of methionine resulted in decrease of the beta -galactosidase activity (Fig. 6B, lanes 2 and 3). These results indicate that these three proteins form a ternary complex in yeast.

We further showed that hGABPalpha , hGABPbeta , and YEAF1 form a ternary complex (Fig. 6B, lanes 4-6). These results together suggest that hGABPalpha , hGABPbeta , YEAF1, and YY1 form a complex, and YEAF1 acts as a bridging factor of the hGABP and YY1 transcription factors.

YEAF1 Repressed and YAF-2 Stimulated Transcriptional Activity of hGABP-- We next examined the effects of YEAF1 and YAF-2 on the biological activity of hGABP. To this end, we measured transcriptional activity of hGABP by transient transfection and a luciferase assay. We used a human retinoblastoma (Rb) gene promoter-luciferase construct (pRb-luciferase) as a reporter (Fig. 7A) and the D. melanogaster Schneider's line 2 (SL2) cell line as a recipient cell, because the Rb promoter contains an hGABP-binding site (12, 13), and SL2 cells contain little endogenous hGABP-like activity (7). As we have reported previously (7), transfection of an expression plasmid containing the DNA-binding subunit hGABPalpha alone had little effect on pRb-luciferase reporter activity (Fig. 7B, lanes 1 and 2), whereas co-expression of the hGABPbeta subunit (but not the hGABPgamma subunit) resulted in significant activation of luciferase activity (Fig. 7B, lanes 5 and 8). Noticeably, co-transfection of an increasing amount of YEAF1 expression plasmid together with hGABPalpha and hGABPbeta resulted in a dose-dependent decrease of luciferase activity (Fig. 7B, lanes 9 and 10), indicating that YEAF1 acts as a transcriptional co-repressor. The repressive effect was not observed when a YEAF1 mutant defective in hGABPbeta binding (CR1OR, see Fig. 3A) was used (Fig. 7B, lanes 11 and 12). Instead, we reproducibly observed an increase of the luciferase activity. Possible explanation for this result will be discussed below.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 7.   Distinct transcriptional effects of YEAF1 and YAF-2 on E4TF1. A, schematic structure of the luciferase reporter construct containing the Rb promoter (pRB-luciferase). B, Schneider's 2 cells co-transfected with pRB-luciferase (0.7 µg), A5CDelta P-beta -galactosidase (0.3 µg), and empty vector (lane 1) or expression vector for hGABPalpha (0.6 µg) (lanes 2-12) in combination with expression vector (0.6 µg) for hGABPgamma (lanes 5-7) or for hGABPbeta (lanes 8-12). The transfection mixture (total 4 µg) also contained an increasing amount (0.6 or 1.8 µg) of expression vector for YEAF1 (lanes 3, 4, 6, 7, 9, and 10) or its deletion mutant YEAF1 (CR1OR) (lanes 11 and 12). Transfection efficiencies were normalized with beta -galactosidase activity, and the data represent the average of three independent experiments. C, luciferase activities of pRB-luciferase (0.7 µg) in Schneider's 2 cells co-transfected with expression vector for hGABPalpha (0.6 µg) and hGABPbeta (0.6 µg) in combination with an increasing amount (0.6 or 1.8 µg) of the expression vector for YAF-2.

In contrast to YEAF1, the transcriptional activity of hGABP was enhanced by co-transfection of an increasing amount of YAF-2, indicating that YAF-2 acts as a transcriptional co-activator for hGABP (Fig. 7C). Therefore, YEAF1 and YAF-2 exhibited opposite effects on the transcriptional activity of hGABP, despite being structurally related.

Tissue Distribution of YEAF1, YAF-2, and hGABPbeta -- We next examined mRNA expression of YEAF1, YAF-2, and hGABPbeta in various tissues using specific DNA probes. A YEAF1 mRNA of about 5 kb was detected in all the tissues we examined, with the highest expression level in placenta (Fig. 8, top panel). Consistent with a previous report that YAF-2 is expressed in muscle cells (26), YAF-2 mRNA expression was the highest in heart and skeletal muscle (Fig. 8, 2nd panel). As we had mentioned previously (8), hGABPbeta mRNA was expressed ubiquitously (Fig. 8, 3rd panel). The expression level of hGABPbeta mRNA was the highest in placenta, heart, and skeletal muscle, where YEAF1 or YAF-2 mRNA were also highly expressed. Although more detailed expression profiling is necessary, these results support the idea that YEAF1 and YAF-2 are tissue-specific cofactors for the hGABP transcription factor.


View larger version (55K):
[in this window]
[in a new window]
 
Fig. 8.   Tissue distribution of mRNAs for YEAF1, YAF-2, and E4TF1. Poly(A)+ RNAs isolated from various human tissues were blotted and hybridized with 32P-labeled probes specific for YEAF1 (top panel), YAF-2 (2nd panel), hGABPbeta /gamma (3rd panel), and actin (bottom panel).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

In this paper, we described the isolation and characterization of YEAF1, a novel interactor of the hGABP/E4TF1 transcription factor. We demonstrated that YEAF1 and its close relative YAF-2 also interact with another transcription factor YY1 and that they act as bridging factors for GABP and YY1. Despite their structural similarity, YEAF1 and YAF-2 were functionally distinct, in that YEAF1 negatively regulated the transcriptional activity of hGABP but YAF-2 positively regulated the activity.

We demonstrated here that YEAF1 and YAF-2 constitute a family of cofactors for the hGABP and YY1 transcription factors. The first identified member, YAF-2, was originally isolated as a factor interacting with YY1 in yeast two-hybrid screening (26). As expected from their sequence similarity, we showed that YEAF1 also interacts with YY1, and YAF-2 interacts with hGABPbeta .

We did not find any other family members of YEAF1 and YAF-2 in a search of the human genome using the GenBankTM data base, but we did identify homologous putative genes, CG12190 and C54H2.3, in the D. melanogaster and Caenorhabditis elegans genomes, respectively,2 suggesting that they are evolutionarily conserved at least among multicellular organisms.

YEAF1 is the human homologue of the mouse RYBP. RYBP was isolated as an interacting partner of Ring1A protein, a member of the Polycomb group (PcG) of proteins (29). The PcG proteins form large complexes that are necessary for the maintenance of the transcriptionally repressed state of a number of genes. It has been shown that RYBP also interacts with another PcG protein, M33, a mouse homologue of Drosophila polycomb (Pc), and with YY1 (29). YY1 has similarity to the Drosophila pleiohomeotic (pho) gene product (30), and accumulating evidence suggests that YY1 is also involved in PcG function (29, 31). Thus, RYBP is considered to be a component of PcG complexes and accordingly acts as a transcriptional repressor when fused with the DNA-binding domain of the GAL4 transcription factor (29). The most plausible model of the repressor function of YEAF1/RYBP is that they recruit PcG complexes. This idea is supported by the recent report (32) that RYBP interacts with the repressor domain of E2F6, a distantly related member of the E2F transcription factors. E2F6 has been shown to form complexes with other PcG proteins such as Ring1, Bmi1, MEL-18, and Mph1.

We demonstrated here that YEAF1 binds to hGABP and represses its transcriptional activity. Therefore, YEAF1/RYBP mediates the transcriptional repression of at least two sequence-specific DNA-binding factors, E2F6 and hGABP. YY1 may also be the target of YEAF1 repression because YY1 can act as a transcriptional repressor depending on the promoter context. It seems consistent that E2F6 (and possibly YY1) actively represses transcription by interacting with PcG complexes. In contrast to E2F6 and YY1, such an active repressor function or active repressor domain has never been assigned to hGABPbeta . Although the YEAF1 interaction domain of hGABPbeta overlaps with the transactivator domain, a more detailed domain analysis may reveal an active repressor domain. Alternatively, YEAF1 may not be able to recruit PcG to hGABP and may reduce the transcriptional activity of hGABP by competition with co-activators such as p300/CBP for binding to hGABP. These two possible mechanisms are not mutually exclusive, and further analysis is necessary to fully understand the molecular mechanism of transcriptional repression by YEAF1.

Despite the similar affinity of YEAF1 and YAF-2 for hGABPbeta , YAF-2 activated hGABP transcriptional activity and YEAF1 repressed it. As far as we know, YEAF1 and YAF-2 are the only structurally related transcriptional cofactors that have opposite functions. It has been reported that the carboxyl-terminal regions of RYBP/YEAF1, OR and CR2, are necessary for transcriptional repressor function. YAF-2 may lack the ability to repress transcription because it lacks the OR domain, and its CR2 region is relatively divergent. If this is the case, one possible explanation for the opposite functions of YEAF1 and YAF-2 is that YAF-2 lacks the ability to bind to PcG complexes. Alternatively, YAF-2 may have an intrinsic transactivation domain. It should be noted that co-expression with hGABP of a truncated YEAF1 protein (CR1OR) that lacks CR2 and the ability to bind to hGABP resulted in an increase of Rb promoter activity (Fig. 7). This mutant YEAF1 may compete for binding to endogenous YEAF1 with PcG complexes, which may lead to accumulation of non-functional PcG complexes and to the activation of transcriptional activity.

We further showed that both hGABP, YEAF1, and YY1 form a ternary complex. As both hGABP and YY1 are sequence-specific DNA-binding proteins, YEAF1 (and probably YAF-2) should be able to bridge hGABP and YY1 when they bind to DNA. It is noteworthy that some promoters contain binding sites for both the hGABP and YY1 transcription factors. For example, the P6 promoter of the human B19 parvovirus contains adjacent hGABP- and YY1-binding sites (33). The activity of this promoter was activated by hGABP and repressed by YY1. Because YEAF1/RYBP is a component of PcG complexes (29), binding of YY1 to the promoter may recruit YEAF1 and PcG complexes to hGABP, which may result in transcriptional repression. This may be not the case for cytochrome c oxidase subunit genes (34), whose promoter regions also contain binding sites for hGABP and YY1, but both of which in this case have been shown to be necessary for efficient transcription. One can speculate that bridging by YAF-2 may enhance transcription by hGABP and YY1. However, a more detailed analysis of the regulation of such promoters is necessary to understand the mechanism of positive and negative regulation by hGABP and YY1. Isolation and characterization of the functionally distinct bridging factors YEAF1 and YAF-2 described here may elucidate the molecular mechanisms of transcriptional regulation by hGABP and YY1, as well as by PcG complexes.

    ACKNOWLEDGEMENTS

We are grateful to S. M. Hollenberg for gifts of the yeast strains and the plasmid pBTM116 and its derivatives and to Dr. T. Yamamoto for assistance with the yeast procedures. We thank T. Shenk for the gift of YY1 cDNA. We also thank Drs. T. Wada and T. Imai for helpful discussions and advice.

    FOOTNOTES

* This work was supported by a grant-in-aid for Scientific Research on Priority Areas from the Ministry of Education, Culture, Sports, Science and Technology and by a grant for Research and Development Projects in cooperation with Academic Institutions from the New Energy and Industrial Technology and Development Organization.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Present address: Dept. of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, 240 Longwood Ave., Boston, MA 02115.

Present address: Dept. of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115.

** To whom correspondence should be addressed: Frontier Collaborative Research Center, Tokyo Institute of Technology, 4259 Nagatsuta-cho, Midori-ku, Yokohama 226-8501, Japan. Tel.: 81-45-924-5872; Fax: 81-45-924-5145; E-mail: hhanda@bio.titech.ac.jp.

Published, JBC Papers in Press, April 12, 2002, DOI 10.1074/jbc. M203060200

2 C. Sawa, T. Yoshikawa, F. Matsuda-Suzuki, S. Deléhouzée, M. Goto, H. Watanabe, J.-i. Sawada, K. Kataoka, and H. Handa, unpublished observations.

    ABBREVIATIONS

The abbreviations used are: E4, adenovirus early 4; YY1, Ying-Yang-1; YAF-2, YY1-associated factor 2; hGABP, human GA-binding protein; YEAF1, YY1- and E4TF1/hGABP-associated factor-1; RYBP, Ring1 and YY1 binding protein; 3-AT, 3-aminotriazol; GST, Glutathione S-transferase; Rb, retinoblastoma susceptibility gene; CR, conserved region, OR, original region; SPR, surface plasmon resonance; PcG, Polycomb group.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Watanabe, H., Imai, T., Sharp, P. A., and Handa, H. (1988) Mol. Cell. Biol. 8, 1290-1300[Abstract/Free Full Text]
2. Watanabe, H., Wada, T., and Handa, H. (1990) EMBO J. 9, 841-847[Medline] [Order article via Infotrieve]
3. Watanabe, H., Sawada, J.-i., Yano, K., Yamaguchi, K., Goto, M., and Handa, H. (1993) Mol. Cell. Biol. 13, 1385-1391[Abstract/Free Full Text]
4. Sawada, J.-i., Goto, M., Sawa, C., Watanabe, H., and Handa, H. (1994) EMBO J. 13, 1396-1402[Medline] [Order article via Infotrieve]
5. LaMarco, K., Thompson, C. C., Byers, B. P., Walton, E. M., and McKnight, S. L. (1991) Science 253, 789-792[Abstract/Free Full Text]
6. Thompson, C. C., Brown, T. A., and McKnight, S. L. (1991) Science 253, 762-768[Abstract/Free Full Text]
7. Sawa, C., Goto, M., Suzuki, F., Watanabe, H., Sawada, J.-i., and Handa, H. (1996) Nucleic Acids Res. 24, 4954-4961[Abstract/Free Full Text]
8. Suzuki, F., Goto, M., Sawa, C., Ito, S., Watanabe, H., Sawada, J.-i., and Handa, H. (1998) J. Biol. Chem. 273, 29302-29308[Abstract/Free Full Text]
9. Virbasius, J. V., Virbasius, C. A., and Scarpulla, R. C. (1993) Genes Dev. 7, 380-392[Abstract/Free Full Text]
10. Villena, J. A., Vinas, O., Mampel, T., Iglesias, R., Giralt, M., and Villarroya, F. (1998) Biochem. J. 331, 121-127[Medline] [Order article via Infotrieve]
11. Genuario, R. R., Kelley, D. E., and Perry, R. P. (1993) Gene Expr. 3, 279-288[Medline] [Order article via Infotrieve]
12. Sowa, Y., Shiio, Y., Fujita, T., Matsumoto, T., Okuyama, Y., Kato, D., Inoue, J., Sawada, J.-i., Goto, M., Watanabe, H., Handa, H., and Sakai, T. (1997) Cancer Res. 57, 3145-3148[Abstract/Free Full Text]
13. Savoysky, E., Mizuno, T., Sowa, Y., Watanabe, H., Sawada, J.-i., Nomura, H., Ohsugi, Y., Handa, H., and Sakai, T. (1994) Oncogene 9, 1839-1846[Medline] [Order article via Infotrieve]
14. Yokomori, N., Kobayashi, R., Moore, R., Sueyoshi, T., and Negishi, M. (1995) Mol. Cell. Biol. 15, 5355-5362[Abstract]
15. Rosmarin, A. G., Caprio, D. G., Kirsch, D. G., Handa, H., and Simkevich, C. P. (1995) J. Biol. Chem. 270, 23627-23633[Abstract/Free Full Text]
16. Nuchprayoon, I., Simkevich, C. P., Luo, M., Friedman, A. D., and Rosmarin, A. G. (1997) Blood 89, 4546-4554[Abstract/Free Full Text]
17. Avots, A., Hoffmeyer, A., Flory, E., Cimanis, A., Rapp, U. R., and Serfling, E. (1997) Mol. Cell. Biol. 17, 4381-4389[Abstract]
18. Khurana, T. S., Rosmarin, A. G., Shang, J., Krag, T. O., Das, S., and Gammeltoft, S. (1999) Mol. Biol. Cell 10, 2075-2086[Abstract/Free Full Text]
19. Gramolini, A. O., Angus, L. M., Schaeffer, L., Burton, E. A., Tinsley, J. M., Davies, K. E., Changeux, J. P., and Jasmin, B. J. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 3223-3227[Abstract/Free Full Text]
20. Schaeffer, L., Duclert, N., Huchet-Dymanus, M., and Changeux, J. P. (1998) EMBO J. 17, 3078-3090[CrossRef][Medline] [Order article via Infotrieve]
21. Sawada, J.-i., Simizu, N., Suzuki, F., Sawa, C., Goto, M., Hasegawa, M., Imai, T., Watanabe, H., and Handa, H. (1999) J. Biol. Chem. 274, 35475-35482[Abstract/Free Full Text]
22. Rosmarin, A. G., Luo, M., Caprio, D. G., Shang, J., and Simkevich, C. P. (1998) J. Biol. Chem. 273, 13097-13103[Abstract/Free Full Text]
23. Galvagni, F., Capo, S., and Oliviero, S. (2001) J. Mol. Biol. 306, 985-996[CrossRef][Medline] [Order article via Infotrieve]
24. Vogel, J. L., and Kristie, T. M. (2000) EMBO J. 19, 683-690[CrossRef][Medline] [Order article via Infotrieve]
25. Morii, E., Ogihara, H., Oboki, K., Sawa, C., Sakuma, T., Nomura, S., Esko, J. D., Handa, H., and Kitamura, Y. (2001) Blood 97, 3032-3039[Abstract/Free Full Text]
26. Kalenik, J. L., Chen, D., Bradley, M. E., Chen, S. J., and Lee, T. C. (1997) Nucleic Acids Res. 25, 843-849[Abstract/Free Full Text]
27. Fields, S., and Song, O. (1989) Nature 340, 245-246[CrossRef][Medline] [Order article via Infotrieve]
28. Shi, Y., Seto, E., Chang, L. S., and Shenk, T. (1991) Cell 67, 377-388[CrossRef][Medline] [Order article via Infotrieve]
29. Garcia, E., Marcos-Gutierrez, C., del Mar Lorente, M., Moreno, J. C., and Vidal, M. (1999) EMBO J. 18, 3404-3418[CrossRef][Medline] [Order article via Infotrieve]
30. Brown, J. L., Mucci, D., Whiteley, M., Dirksen, M. L., and Kassis, J. A. (1998) Mol. Cell 1, 1057-1064[CrossRef][Medline] [Order article via Infotrieve]
31. Satijn, D. P., Hamer, K. M., den Blaauwen, J., and Otte, A. P. (2001) Mol. Cell. Biol. 21, 1360-1369[Abstract/Free Full Text]
32. Trimarchi, J. M., Fairchild, B., Wen, J., and Lees, J. A. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 1519-1524[Abstract/Free Full Text]
33. Vassias, I., Hazan, U., Michel, Y., Sawa, C., Handa, H., Gouya, L., and Morinet, F. (1998) J. Biol. Chem. 273, 8287-8293[Abstract/Free Full Text]
34. Lenka, N., Vijayasarathy, C., Mullick, J., and Avadhani, N. G. (1998) Prog. Nucleic Acids Res. Mol. Biol. 61, 309-344[Medline] [Order article via Infotrieve]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
GeneticsHome page
I. Gonzalez, R. Aparicio, and A. Busturia
Functional Characterization of the dRYBP Gene in Drosophila
Genetics, July 1, 2008; 179(3): 1373 - 1388.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
F. S. Santiago, H. Ishii, S. Shafi, R. Khurana, P. Kanellakis, R. Bhindi, M. J. Ramirez, A. Bobik, J. F. Martin, C. N. Chesterman, et al.
Yin Yang-1 Inhibits Vascular Smooth Muscle Cell Growth and Intimal Thickening by Repressing p21WAF1/Cip1 Transcription and p21WAF1/Cip1-Cdk4-Cyclin D1 Assembly
Circ. Res., July 20, 2007; 101(2): 146 - 155.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. E. Stanton, L. J. McReynolds, T. Evans, and N. Schreiber-Agus
Yaf2 Inhibits Caspase 8-mediated Apoptosis and Regulates Cell Survival during Zebrafish Embryogenesis
J. Biol. Chem., September 29, 2006; 281(39): 28782 - 28793.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
M. K. Pirity, J. Locker, and N. Schreiber-Agus
Rybp/DEDAF Is Required for Early Postimplantation and for Central Nervous System Development
Mol. Cell. Biol., August 15, 2005; 25(16): 7193 - 7202.
[Abstract] [Full Text] [PDF]


Home page
GENES CELLSHome page
S. Delehouzee, T. Yoshikawa, C. Sawa, J.-i. Sawada, T. Ito, M. Omori, T. Wada, Y. Yamaguchi, Y. Kabe, and H. Handa
GABP, HCF-1 and YY1 are involved in Rb gene expression during myogenesis
Genes Cells, July 1, 2005; 10(7): 717 - 731.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
P. Zheng, B. Patel, M. McMenamin, A. M. Paprocki, R. D. Schramm, N. G. Nagl Jr, D. Wilsker, X. Wang, E. Moran, and K. E. Latham
Expression of Genes Encoding Chromatin Regulatory Factors in Developing Rhesus Monkey Oocytes and Preimplantation Stage Embryos: Possible Roles in Genome Activation
Biol Reprod, May 1, 2004; 70(5): 1419 - 1427.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. J. Gordon, S. Saleque, and B. K. Birshtein
Yin Yang 1 Is a Lipopolysaccharide-Inducible Activator of the Murine 3' Igh Enhancer, hs3
J. Immunol., June 1, 2003; 170(11): 5549 - 5557.
[Abstract] [Full Text] [PDF]